Expertise in
65
conditions

Dr. Sridhar R. Bolla

Hematology | Oncology
Hendricks Oncology
100 Hospital Ln Ste 320, 
Danville, IN 
Accepting New Patients
Offers Telehealth
Expertise in
65
conditions
Hendricks Oncology
100 Hospital Ln Ste 320, 
Danville, IN 

Overview

Sridhar Bolla is a Hematologist and an Oncologist practicing medicine in Danville, Indiana.

Dr. Bolla is highly rated in 65 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 3 clinical trials. Dr. Bolla is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health
Putnam County Hospital
Hendricks Regional Health
Iu Health West Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 14 Less Insurance Carriers -

Locations

Hendricks Oncology
100 Hospital Ln Ste 320, Danville, IN 46122
Other Locations
Hendricks Oncology
8244 E US Highway 36 Ste 1340, Avon, IN 46123

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 2 Less Clinical Trials

1 Total Publications

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Journal: Gynecologic oncology case reports
Published: March 25, 2013
Similar Doctors
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (20.8 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis. Dr. Shapiro is currently accepting new patients.

Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (19.8 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rushing is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, and Bone Tumor.

Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Referral may be required

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (19.7 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Rhodes is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rhodes is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, RASopathies, and Malignant Peripheral Nerve Sheath Tumor. Dr. Rhodes is currently accepting new patients.

Frequently Asked Questions about Dr. Sridhar R. Bolla

How do I make an appointment with Dr. Sridhar R. Bolla?

You can book an appointment with Dr. Sridhar R. Bolla by calling their office at 317-451-4639. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sridhar R. Bolla a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sridhar R. Bolla is classified as an Distinguished expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sridhar R. Bolla specialize in?

While Dr. Sridhar R. Bolla is a Hematology, they have specific expertise in Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sridhar R. Bolla participate in research or clinical trials?

Yes. Dr. Sridhar R. Bolla has published 1 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Dr. Sridhar R. Bolla's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sridhar R. Bolla accept my insurance?

Dr. Sridhar R. Bolla accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-451-4639 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bolla's expertise for a condition
ConditionClose
    View All 24 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 112 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile